CPI launches RNA Centre of Excellence

The Centre for Process Innovation (CPI), a UK-based technology innovation centre and part of the High Value Manufacturing Catapult, launches RNA Centre of Excellence.

The £26.4 million RNA Centre of Excellence will form a UK hub with the capability to develop and manufacture treatments for incurable or hard-to-treat illnesses.

The Centre has the capacity to deliver 100 million vaccine doses in the event of a future health emergency. But it will also supply material for clinical trials, working on treatments against infectious and non-infectious diseases – a critical step in getting new, more effective drugs to patients.

At launch, the Centre is the only open access facility in the UK which can produce lipid nanoparticle-encapsulated messenger and self-amplifying RNA vaccines and therapies. Providing much-needed infrastructure and outstanding expertise, it will promote access to innovative vaccines in both the UK and around the world.

This unique suite of innovation support combines product and process development with scale up and clinical production in both mRNA manufacture and lipid encapsulation at a single site. This will help cement UK leadership in the development and commercialisation of innovative RNA products and processes and attract inward investment and promote resilience and sustainable growth in the UK healthcare ecosystem.

Pivotal support and expertise

Having played a key role in the accelerated development of COVID-19 vaccines as part of the UK Government’s Vaccine Taskforce, CPI has built the knowledge and networks to support every stage of RNA development and scale-up. We are already working with pioneering partners to drive forward a variety of RNA projects, including a first-of-its-kind saRNA flu vaccine in collaboration with VaxEquity. 

Funded by the Department for Science, Innovation and Technology (DSIT), the RNA Centre of Excellence provides pivotal support and expertise in the UK for groundbreaking development, scale-up, and manufacture of new RNA therapies and vaccines. 

To celebrate the launch, an event was held on Thursday, 21 September to open the new facility. George Freeman MP, Minister of State at the Department for Science, Innovation and Technology, was in attendance to cut the ribbon and officially open the new Centre.

Frank Millar, CEO at CPI said: “Lipid nanoparticle-encapsulated messenger and self-amplifying RNA vaccines and therapies have huge potential. These new technologies, which were utilised throughout the COVID-19 pandemic are set to light the touchpaper on the race to develop therapeutics and treatments for incurable diseases. 

“This is a landmark day for CPI and our work to drive forward new technologies in health, and I would like to thank those involved who have worked tirelessly to see this centre through to its launch today. But, it is also a landmark day in scaling up the UKs ability to develop new vaccines and therapeutics, as well as safeguard us against future health emergencies. 

“These new techniques for developing treatments could provide the UK, and the world with the ability to save or make life-changing improvements to patient outcomes.”

Minister of State at the Department for Science, Innovation and Technology, George Freeman, said: “We have learnt the lessons from the Covid-19 pandemic, remembering the crucial role rapid vaccine development, delivered at scale, had in saving lives and safely restoring our freedoms. 

“That is why we are building on the UK’s life sciences prowess and backing the RNA Centre of Excellence through £26 million of Government funding, which will strengthen future pandemic preparedness, boost pioneering work to tackle the most hard-to-treat diseases and grow our economy through innovation.” 

 

More news and updates 

ImmuONE is celebrating triple triumph at the inspiring herts awards 2024

We’re proud to announce that ImmuONE took home the prestigious award for ‘Business of the Year – North Herts’, which was awarded to us for consistent growth, robust financial performance, and unwavering commitment to staff and innovation. From the pool of winners, there was also a special recognition category which honoured ImmuONE with the ‘Inspiring Business of the Year’ award for making the biggest innovation in Hertfordshire.

Cryoport systems officially launches global supply chain hub in Stevenage

Cryoport, Inc a global leader in innovative supply chain solutions for the cell and gene therapy industry, is thrilled to announce the official launch of the Cryoport Systems state-of-the-art Global Supply Chain Hub in Stevenage, U.K.

Microbiotica to present positive update on manufacturing progress of its live biotherapeutic products

Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines announces that Adam Wilkinson, its Vice President of Pre-Clinical Development, will present an overview of the company’s successful product manufacturing campaigns ahead of its forthcoming melanoma and ulcerative colitis clinical studies at the 9th Microbiome Movement Drug Development Summit, on 11 July, in Boston, USA, together with Claire Derlot, CBO from its GMP manufacturing partner Biose Industrie.

Milner Institute celebrates success of 2024 Pitch Day and therapeutics symposium

The Milner Therapeutics Institute were delighted to host two sell-out events in Cambridge that brought academics, investors, pharma and biotech companies together.

Moa harvests global deal for new herbicide

Moa Technology has signed a major research and commercial agreement with Australian ag giant Nufarm. The deal will see Moa receiving receive upfront payments, milestone development payments and royalties in return for Nufarm gaining exclusive access to a product in one of Moa's breakthrough novel mode of action areas.

Myricx Bio announces £90 million Series A financing to advance its novel NMTi-ADC therapeutics into clinical development

£90 million ($114 million) series A co-led by new leading life science investors Novo Holdings and Abingworth; additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners.

NCIMB Ltd kicks off innovative enzyme technology development project

Aberdeen-based biotechnology company NCIMB has kicked-off a new research project to demonstrate novel enzyme technology with an exciting array of potential applications in the pharmaceutical, food & drink and environmental sectors.

Promising results from cardiac fibrosis studies with MRX1

Ananda Developments PLC, a clinical-stage life sciences company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is delighted to share promising results from recent preclinical studies investigating the efficacy of MRX1 (Patent Pending) in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF).

Valneva Scotland appoints science communications consultancy, Perceptive Communicators

Glasgow-based specialist communications consultancy, Perceptive Communicators, has announced its appointment to provide strategic communications services for Valneva Scotland.

Coulter Partners places Head of Sales North America at Pelago Bioscience

Coulter Partners recently partnered with Pelago Bioscience and is pleased to announce the placement of Brian Jarecki, PhD as Head of Sales North America.

 

More within